Rani Therapeutics

Yahoo Finance • 10 days ago

Rani Therapeutics to Participate in the Evercore Healthcare Conference

SAN JOSE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today anno... Full story

Yahoo Finance • 28 days ago

Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update

– Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics – – Completed $60.3 million oversubscribed private placement led by Samsara BioCapital with participation from RA Capital M... Full story

Yahoo Finance • last month

Trending tickers: Apple, Beyond Meat, Rani Therapeutics, BitMine and B&M

Apple (AAPL) Shares in Apple (AAPL) edged up just 0.3% in pre-market trading on Monday, despite fresh data indicating that early sales of its iPhone 17 series have outperformed last year’s model in China and the United States. According... Full story

Yahoo Finance • 2 months ago

Rani Therapeutics (RANI) Is Up 257.9% After $1.08 Billion Chugai Deal and $60M Fundraise—What’s Changed

Rani Therapeutics Holdings recently announced a collaboration and license agreement with Chugai Pharmaceutical for the joint development and commercialization of an oral product combining Rani’s RaniPill oral delivery technology and Chugai... Full story

Yahoo Finance • 2 months ago

Top Midday Gainers

Rani Therapeutics (RANI) said on Friday that it signed a collaboration and licensing agreement value PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 2 months ago

Rani Therapeutics Announces Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules

Financing led by Samsara BioCapital, L.P. (“Samsara”) with participation from additional investors, including RA Capital Management, Anomaly, Special Situations Funds,Invus and Mr. Mir ImranAt the closing of the financing, each of Samsara... Full story

Yahoo Finance • 2 months ago

Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 Million Financing

Rani will receive $10 million upfront payment and is eligible to receive up to $75 million in technology transfer and development milestones, up to $100 million in sales milestones and single digit royalties on product sales for the first... Full story

Yahoo Finance • 5 months ago

Rani Therapeutics stock plunges after $3 million registered direct offering

Investing.com -- Rani Therapeutics Holdings Inc (NASDAQ:RANI) stock plunged 35.8% after the clinical-stage biotherapeutics company announced a registered direct offering that will raise approximately $3 million in gross proceeds. The co... Full story

Yahoo Finance • 5 months ago

Rani Therapeutics announces $3M registered direct offering; shares down nearly 31%

* Rani Therapeutics (NASDAQ:RANI [https://seekingalpha.com/symbol/RANI]) has entered a securities purchase agreement with a single institutional investor for a $3M registered direct offering. * The deal includes the sale of .35M Class... Full story

Yahoo Finance • 5 months ago

Rani Therapeutics stock soars after announcing ENDO 2025 presentation

Investing.com -- Rani Therapeutics Holdings Inc (NASDAQ:RANI) stock surged 18% after the clinical-stage biotherapeutics company announced it will present preclinical data on its RaniPill capsule at the Endocrine Society’s Annual Meeting... Full story

Yahoo Finance • 5 months ago

Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery 

SAN JOSE, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today anno... Full story

Yahoo Finance • 5 months ago

Rani Therapeutics files to sell 13.16M shares of Class A common stock by selling shareholders

* Rani Therapeutics (NASDAQ:RANI [https://seekingalpha.com/symbol/RANI]) filed a prospectus to sale 13.16 million shares of class A common stock. * The company will not receive any proceeds from the sale of ordinary shares by the selli... Full story

Yahoo Finance • 7 months ago

Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update

- Announced preclinical data demonstrating the bioequivalence of RT-114, a bispecific GLP-1/GLP-2 receptor agonist (PG-102), delivered orally via the RaniPill® capsule, to subcutaneous administration of PG-102 - - Phase 1 study for RT-114... Full story

Yahoo Finance • 8 months ago

Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update

- Announced preclinical data demonstrating the bioequivalence of RT-114, a GLP-1/GLP-2 dual agonist (PG-102) delivered orally via the RaniPill® capsule, to subcutaneous administration of PG-102 - - Announced preclinical data demonstrating... Full story

Yahoo Finance • 8 months ago

Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102

- RT-114 yielded a relative bioavailability of 111% compared to PG-102 delivered subcutaneously with comparable PK profiles, meeting the primary endpoint of demonstrating bioequivalence– - Both groups demonstrated comparable weight loss w... Full story

Yahoo Finance • 8 months ago

Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

SAN JOSE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today ann... Full story

Yahoo Finance • 2 years ago

Rani Therapeutics Announces Strategic Program Prioritization, Expansion of Manufacturing and Plans to Streamline Business Operations to Support Near-Term Value Drivers and Long-Term Growth of the RaniPill® Technology Platform; Reports Preliminary Third Quarter 2023 Financial Results

- Cash runway extended into 2025 - - Cash runway expected to extend beyond topline results from Phase 2 trial for RT-102, topline results from Phase 1 trial for RT-111, and development of RaniPill® HC to be Phase 1 ready - - Expansion of... Full story

Yahoo Finance • 2 years ago

The RaniPill® Capsule, Rani Therapeutics’ Oral Delivery Platform, was Well-Tolerated in 60-Day, Repeat-Administration, GLP Safety Study

– Daily administration for 60 days was well-tolerated with no treatment-related adverse events – – Preclinical data support the safety and tolerability of RaniPill® capsule for subsequent clinical studies – SAN JOSE, Calif., Oct. 25, 20... Full story

Yahoo Finance • 2 years ago

Rani Therapeutics Announces Successful Oral Delivery of Monoclonal Antibody via High-Capacity Pill in Preclinical Study

- RaniPill®HC achieved 4/4 successful drug delivery of orally administered Humira® (adalimumab) - - RaniPill® HC has achieved a cumulative >90% success rate across multiple preclinical studies – - RaniPill® HC shortlisted as a finalist b... Full story

Yahoo Finance • 2 years ago

Rani Therapeutics to Present Abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research

SAN JOSE, Calif., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today anno... Full story